Slaying the pre-TCR beast

IF 66.8 1区医学 Q1 ONCOLOGY

Nature Reviews Cancer Pub Date : 2025-09-22 DOI:10.1038/s41568-025-00880-1

Gabrielle Brewer

引用次数: 0

Abstract

In a study published in Nature Immunology, Fuentes et al. demonstrate that the pre-T cell receptor (TCR) is expressed in leukaemia-initiating cells in patients with T cell acute lymphoblastic leukaemia, and that targeting it can inhibit tumour progression.

Abstract Image

查看原文本刊更多论文

杀死tcr之前的野兽。

在Nature Immunology上发表的一项研究中，Fuentes等人证实T细胞急性淋巴细胞白血病患者的白血病起始细胞中表达T细胞前受体（pre-T cell receptor， TCR），靶向它可以抑制肿瘤进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Cancer 医学-肿瘤学

CiteScore

111.90

自引率

0.40%

发文量

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Cancer, a part of the Nature Reviews portfolio of journals, aims to be the premier source of reviews and commentaries for the scientific communities it serves. The correct abbreviation for abstracting and indexing purposes is Nat. Rev. Cancer. The international standard serial numbers (ISSN) for Nature Reviews Cancer are 1474-175X (print) and 1474-1768 (online). Unlike other journals, Nature Reviews Cancer does not have an external editorial board. Instead, all editorial decisions are made by a team of full-time professional editors who are PhD-level scientists. The journal publishes Research Highlights, Comments, Reviews, and Perspectives relevant to cancer researchers, ensuring that the articles reach the widest possible audience due to their broad scope.